In more than 3 million people worldwide treated for hypertension, ARBs were not only just as effective as ACE inhibitors at reducing the risk of major cardiovascular events, but also associated with a ...

Close-up of senior black woman sorting weekly medication. Member of a black middle class America family. Currently, ACE inhibitors and ARBs are both recommended as first-line therapies for the ...

In the largest comparison of angiotensin receptor blockers (ARBs) and angiotensin-converting enzyme (ACE) inhibitors to date, a study of nearly 2.3 million patients starting the drugs as monotherapy ...

The first study of its kind reports that patients should keep taking well-known heart medications. Patients with heart conditions that require angiotensin-converting enzyme (ACE) inhibitors and ...

Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. The first randomized study to compare continuing vs stopping angiotensin-converting enzyme (ACE) ...

(UPDATED) Hospitalized patients with COVID-19 who continue on their previously prescribed ACE inhibitors and ARBs are not at an increased risk of dying or remaining in the hospital when compared to ...

(HealthDay News) — Angiotensin receptor blockers (ARBs) are just as effective and safe as angiotensin-converting enzyme inhibitors (ACEIs), according to research published in Mayo Clinic Proceedings.

Please provide your email address to receive an email when new articles are posted on . In patients hospitalized with mild or moderate COVID-19, suspending ACE inhibitors and angiotensin receptor ...

Washington, DC (December 8, 2011) — Two seemingly similar blood pressure–lowering drugs have different effects on the heart health of dialysis patients, according to a study appearing in an upcoming ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Use of ACE inhibitors and angiotensin receptor blockers ...

Stopping an ACE inhibitor or angiotensin receptor blocker (ARB) at admission for COVID-19 doesn't help outcomes, even for high-risk groups, the BRACE CORONA randomized trial showed. Continuing these ...